Search research articles
Contact Us
Filters
Showing results (151-160 of 157) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 157 results.
American Journal of Clinical Oncology
|
February 22, 2000
A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer
Y M Chen, R P Perng, K Y Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 1998
Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients
C L Lai, C M Tsai, T T Tsai, et al.
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|
August 12, 1998
Ifosfamide-based chemotherapy for previously treated lung cancer patients
Y M Chen, J M Liu, M F Wu, et al.
Japanese Journal of Clinical Oncology
|
April 1, 1997
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer
Y M Chen, M F Wu, R P Perng, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 1997
Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients
Y M Chen, W K Yang, J Whang-Peng, et al.
American Journal of Clinical Oncology
|
February 22, 2000
A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non--small-cell lung cancer
R P Perng, J F Shih, Y M Chen, et al.
British Journal of Cancer
|
March 1, 2002
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
C H Yang, C M Tsai, L S Wang, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 157) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 157 results.
American Journal of Clinical Oncology
|
February 22, 2000
A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer
Y M Chen, R P Perng, K Y Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 1998
Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients
C L Lai, C M Tsai, T T Tsai, et al.
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|
August 12, 1998
Ifosfamide-based chemotherapy for previously treated lung cancer patients
Y M Chen, J M Liu, M F Wu, et al.
Japanese Journal of Clinical Oncology
|
April 1, 1997
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer
Y M Chen, M F Wu, R P Perng, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 1997
Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients
Y M Chen, W K Yang, J Whang-Peng, et al.
American Journal of Clinical Oncology
|
February 22, 2000
A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non--small-cell lung cancer
R P Perng, J F Shih, Y M Chen, et al.
British Journal of Cancer
|
March 1, 2002
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
C H Yang, C M Tsai, L S Wang, et al.
Page
of 16